DPP4 and metabolic dysfunction-associated steatohepatitis: The protective effect of anti-diabetic drugs is also confirmed for other classes of drugs, such as dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter-2 (SGLT2) inhibitors, as demonstrated in the NASH-related HCC mouse models [78,79].